Allied Health & Imaging · Independent exam preparation

CCRC® Preparation Guide: Coordinator Decisions in Clinical Research Study Guide

Practise CCRC decisions in consent, safety reporting, trial conduct, product accountability and data integrity through 60 focused concepts and original learning drills.

By CertMedbry · Updated 30 October 2026

60 concepts explainedWorked examples & common pitfallsOfficial blueprint references

Practise deciding whether consent is adequate, a safety event needs escalation, a product can be dispensed, and a trial record supports a reliable conclusion. This guide follows the Certified Clinical Research Coordinator pathway and the six domains of ACRP's linked 2024 Examination Content Outline, using the E6(R3) examination-reference transition effective July 15, 2026. Its 60 concepts are selective: the official outline's complete knowledge and task statements define the full examination scope.

Try 20 free practice questions

What is the exam format?

Check the question types, timing and outline before planning your revision.

Which credential and professional role does this guide cover?

This guide covers the Certified Clinical Research Coordinator (CCRC®) examination. ACRP identifies the role as coordinating clinical trials under a principal investigator. The Academy of Clinical Research Professionals, ACRP's independent affiliate, develops and administers the certification program.

ACRP — CCRC Certification · ACRP Certification Handbook — June 2026

How many questions are on the examination, and how much time is allowed?

The issuer information identifies 125 multiple-choice questions and 180 minutes. That permits an average of 1.44 minutes per question, although candidates can distribute their time according to question complexity.

ACRP — CCRC Certification

How many questions are scored or pretest, and which item styles are verified?

The 125 questions include 100 scored questions and 25 unidentified, unscored pretest items. Each item has four answer options and one best answer. Because pretest items are not identified, answer every question. The June 2026 Certification Handbook describes this structure on page 6. The 20 questions here are independent four-option, single-best-answer learning drills.

ACRP Certification Handbook — June 2026

Is delivery adaptive, and which testing arrangements are verified?

Candidates select PSI test-center delivery or live remote proctoring when scheduling, as described on page 15 of the June 2026 Certification Handbook. Delivery method and adaptivity are separate features: these delivery choices do not establish whether the examination is adaptive.

ACRP Certification Handbook — June 2026

Which blueprint applies, and how are its domains weighted?

The currently linked 2024 outline assigns Scientific Concepts and Research Design 8%, Ethical and Participant Safety Considerations 19%, Product Development and Regulation 13%, Clinical Trial Operations (GCPs) 23%, Study and Site Management 22%, and Data Management and Informatics 15%. Its currency was verified October 12, 2026, and the outline was confirmed again October 30, 2026. It prints no separate day/month implementation date. This guide allocates concepts 5, 11, 8, 14, 13, and 9 across those domains; questions and flashcards each use 2, 4, 3, 4, 4, and 3.

2024 Examination Content Outline: CCRC® Certification · ACRP Certification Handbook — June 2026

How do the E6(R3) guideline date and examination transition date differ?

ICH adopted the final E6(R3) guideline on January 6, 2025. ACRP replaced E6(R2) with E6(R3) as an examination reference beginning July 15, 2026. Those dates describe different events. The June 2026 handbook lists E6(R3) among the examination references.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · ACRP — CCRC Certification · ACRP Certification Handbook — June 2026

Which references and jurisdictions should guide preparation?

The June 2026 handbook lists E6(R3), E2A, E8(R1), E9, E9(R1), E11(R1), and the Declaration of Helsinki. ACRP states that country-specific regulatory frameworks are excluded from the examination reference scope. Learn the international principles and recognize when actual trial conduct also requires applicable local approvals, reporting rules, and institutional procedures.

ACRP — CCRC Certification · ACRP Certification Handbook — June 2026

CCRC is a professional certification for clinical research coordinators working under a principal investigator. These independently authored learning materials apply international research standards to coordinator decisions; they are not official examination questions or a prediction of examination performance.

Outline used: 2024 Examination Content Outline: CCRC® Certification, currently linked by ACRP and corroborated by the June 2026 Certification Handbook; verified on 2026-10-12. ACRP's E6(R3) examination-reference transition took effect July 15, 2026. The workbook label matches the current official credential; the assigned slug is preserved.

60 key concepts: understand, apply and avoid the traps

Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.

Scientific Concepts and Research Design8%

1.How do the protocol and Investigator's Brochure support different decisions?

The protocol defines the study's objectives, design, procedures, eligibility rules, and planned analyses. The Investigator's Brochure integrates relevant nonclinical and clinical information about the investigational product, supporting understanding of its risks and appropriate use. Read them together when assessing a proposed activity or emerging event. A product risk described in the brochure does not independently authorize changing a protocol procedure or eligibility threshold.

Apply it

A coordinator finds that dizziness is discussed in an updated brochure, while the protocol specifies scheduled post-dose observations. The coordinator alerts the investigator to the new information and confirms whether additional approved instructions or consent updates are required.

Common pitfall: Treating the brochure as a replacement protocol can lead to unauthorized procedural changes. Product knowledge informs judgment but does not rewrite study requirements.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

2.Why must eligibility criteria be applied exactly as written?

Eligibility criteria define the population in which the study question can be answered with an acceptable risk-benefit balance. They may control safety risks, reduce confounding, or establish a consistent disease state. Confirm each criterion using the specified evidence and assessment window before enrollment. A participant who seems clinically suitable can still be ineligible; personal judgment cannot replace a defined threshold or a required diagnostic confirmation.

Apply it

A protocol requires a laboratory value of at least 50 units within seven days before randomization. A candidate's result is 49 units. The coordinator flags the exclusion and checks whether protocol-permitted repeat testing is available.

Common pitfall: Rounding a result upward or accepting a sponsor's informal reassurance undermines eligibility. Any repeat assessment must follow the protocol rather than create an exception.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · ICH E8(R1) — General Considerations for Clinical Studies

3.How do objectives, endpoints, comparators, and rescue treatment fit together?

An objective states the scientific question; an endpoint specifies the observation used to answer it. The comparator establishes the reference against which an intervention is evaluated. Rescue treatment protects participants when additional care is needed, but its use can affect interpretation of outcomes. Identify the endpoint's measurement, timing, and handling of rescue treatment rather than assuming that any clinically relevant improvement answers the primary study question.

Apply it

A trial's primary endpoint is symptom score at week 12, while rescue medication is allowed for worsening symptoms. The coordinator records rescue use and continues scheduled assessments because both observations help interpret the prespecified treatment comparison.

Common pitfall: Substituting a convenient measurement or omitting outcomes after rescue treatment changes the question being answered and may introduce bias into the comparison.

ICH E9 — Statistical Principles for Clinical Trials · ICH E9(R1) — Addendum on Estimands and Sensitivity Analysis in Clinical Trials

4.Which biases do randomization, allocation concealment, and blinding address?

Randomization assigns treatments through a chance process to support comparable groups. Allocation concealment prevents advance knowledge of the next assignment from influencing enrollment. Blinding limits changes in care, reporting, or assessment caused by knowing treatment. These protections serve different purposes. In crossover studies, participants receive different treatments in successive periods; residual effects and period effects require attention even when the treatment sequence is randomized and blinded.

Apply it

A recruiter can predict the next assignment from an alternating sequence and delays an enrollment. The coordinator recognizes compromised allocation concealment and escalates the issue, even though outcome assessors remain unaware of participants' treatments.

Common pitfall: Calling a study blinded does not prove enrollment was protected from selection bias. Predictable treatment assignment is not equivalent to a valid randomization process.

ICH E9 — Statistical Principles for Clinical Trials

5.How should screening rates inform recruitment planning?

A screen-failure rate uses the number failing screening divided by the number screened within a defined group and period. Its complement estimates the eligible proportion when categories are complete. Divide the enrollment target by the expected eligible proportion to estimate screening needs, then consider consent and retention separately. Sample size concerns the information required for the scientific objective; it is not automatically the number a site must screen.

Apply it

A site needs 60 enrolled participants and expects 25% of screened candidates to fail eligibility. Assuming every eligible candidate enrolls, it plans to screen 80 people, then adds separate allowances for refusal and later withdrawal.

Common pitfall: Adding 25% to the enrollment target produces 75, which is insufficient. The correct calculation divides by the expected eligible proportion of 0.75.

ICH E9 — Statistical Principles for Clinical Trials · ICH E8(R1) — General Considerations for Clinical Studies

Ethical and Participant Safety Considerations19%

6.How does adverse-event seriousness differ from severity?

Severity describes intensity, such as mild, moderate, or severe. Seriousness depends on outcomes or circumstances, including death, actual life-threatening danger, inpatient hospitalization or its prolongation, significant disability, congenital anomaly, or another medically important event. A severe symptom can be nonserious, while a less intense event can be serious. Classify both dimensions separately and obtain investigator assessment when medical judgment is needed to interpret consequences or required intervention.

Apply it

One participant has severe nausea treated at home; another has moderate weakness requiring an unplanned inpatient admission. The coordinator records intensity for both and promptly brings the hospitalization to the investigator's attention for serious-event handling.

Common pitfall: Using the word severe as a substitute for serious can misroute reports. Hospitalization and other seriousness criteria require assessment independently of symptom intensity.

ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting

7.How are causality and expectedness assessed independently?

An adverse event does not require a causal relationship to treatment. An adverse reaction involves at least a reasonable possibility of a causal relationship. Expectedness compares the reaction's nature or severity with applicable reference safety information; simply knowing that a broad organ-system problem can occur is insufficient. Record the event and obtain the appropriate medical assessments without assuming that temporal association establishes causation or that prior mention makes every presentation expected.

Apply it

A participant develops a serious liver injury after treatment. The brochure mentions mild transient enzyme increases. The coordinator provides the investigator with timing, laboratory trends, alternative causes, and the reference description to support separate causality and expectedness assessments.

Common pitfall: Labeling every post-dose event related, or every broadly similar event expected, collapses distinct assessments and can lead to inappropriate safety-reporting decisions and records.

ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting

8.What makes informed consent a valid process?

Informed consent requires understandable information, adequate opportunity for questions, voluntary choice, and appropriate documentation before research participation begins. Explain purpose, procedures, foreseeable risks, potential benefits, alternatives, confidentiality, and withdrawal rights using the approved materials. Assess understanding rather than relying on a signature alone. Electronic consent must preserve the same protections, including appropriate identity verification, access to information, and documentation of the discussion and agreement.

Apply it

A candidate signs an electronic form but says the study guarantees improvement. Before any research procedure, the coordinator revisits uncertainty, alternatives, and random assignment, checks understanding in the candidate's own words, and documents the discussion.

Common pitfall: A completed signature field cannot cure a material misunderstanding. Efficiency, prior clinical relationships, or familiarity with technology does not remove the need for discussion.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · Interpretation and Application of ICH E6(R3) — Informed Consent Training Transcript

9.When must new information be discussed with enrolled participants?

Consent continues throughout participation. New information that could affect willingness to remain must be communicated promptly through an appropriate discussion, with documentation and revised consent materials when required. Ethics review of revisions remains necessary, but urgent participant protection cannot wait for routine administrative processing. Distinguish merely distributing an updated document from explaining how the new information changes the participant's choices, procedures, or understanding of risk.

Apply it

A new safety finding introduces an additional serious risk and a monitoring procedure. The coordinator works with the investigator to inform affected participants promptly, manage immediate safety needs, and obtain required approval and documentation for revised consent.

Common pitfall: Waiting until the next annual consent review can leave participants making decisions with outdated information. A new signature without explanation also misses the purpose.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · Interpretation and Application of ICH E6(R3) — Informed Consent Training Transcript

10.How should assent and permission adapt as a child matures?

Pediatric participation generally combines permission from the legally authorized person with the child's involvement according to maturity and capacity. Assent is an affirmative, age-appropriate expression of willingness, not mere silence. Revisit information as understanding develops. When a participant gains legal capacity to consent during a continuing study, obtain their own informed consent as applicable. Protection depends on individual circumstances and applicable law, rather than a universal age threshold.

Apply it

A participant enrolled through parental permission becomes legally able to consent while follow-up continues. The coordinator arranges a direct consent discussion with the participant and documents their decision before further participation requiring their authorization.

Common pitfall: Assuming the original parental signature automatically covers adulthood overlooks the participant's changed legal authority. Equating lack of protest with assent is also inadequate.

ICH E11(R1) — Clinical Investigation of Medicinal Products in the Pediatric Population

11.How can privacy be protected while enabling authorized source review?

Privacy concerns access to a person's circumstances and information; confidentiality concerns how entrusted information is handled. Authorized trial review may require access to identifiable source records, but access must remain limited to legitimate purposes and protected channels. Explain relevant access during consent, verify reviewer authorization, and disclose only what the review requires. A coded dataset remains potentially identifiable when a link to the participant is retained elsewhere.

Apply it

A monitor requests records for three enrolled participants. The coordinator arranges authorized access to their relevant records, protects unrelated patients' information, and keeps the participant identification list within the site's controlled record system during review.

Common pitfall: Calling records coded does not make unrestricted sharing acceptable. Conversely, confidentiality does not justify blocking properly authorized review of relevant study source records altogether.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

12.When is emergency unblinding justified?

Emergency unblinding is justified when treatment knowledge is necessary for appropriate clinical management. The investigator must be able to obtain that information without undue delay using the established procedure. Limit disclosure to people who need it, document why and when the blind was broken, and notify relevant parties as required. An adverse event alone does not automatically justify unblinding when care can proceed safely without treatment identity.

Apply it

An emergency physician explains that immediate management differs materially between the two study treatments. The investigator uses the emergency code-break system, documents the clinical reason, and limits treatment disclosure so other participants' assessments remain protected from bias.

Common pitfall: Waiting for routine sponsor office hours can delay necessary care. Opening every participant's assignment after one emergency would create unnecessary additional loss of blinding.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

13.How should an immediate-hazard protocol deviation be handled?

Protocol changes normally require the appropriate prior approvals. An exception permits action needed to eliminate an immediate hazard to participants. Take the necessary protective action, document the circumstances and departure, and promptly inform the sponsor and ethics committee as required. The exception is narrow: inconvenience, recruitment pressure, or a potentially helpful routine improvement does not establish an immediate hazard or authorize unrestricted changes to study conduct.

Apply it

A participant develops an acute reaction during a required procedure. The investigator stops it to prevent further harm. The coordinator records the event, clinical actions, and protocol departure, then facilitates required notifications and follow-up documentation promptly.

Common pitfall: Obtaining approval before stopping an immediately hazardous procedure reverses the protection priority. Calling a scheduling problem an emergency improperly expands the exception beyond safety.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

14.How does treatment discontinuation differ from withdrawal from follow-up?

Stopping assigned treatment does not necessarily end study participation. A participant may discontinue product while agreeing to outcome collection, safety contacts, or other follow-up. Clarify the person's wishes without pressure and follow the protocol's approach to post-discontinuation data. For a treatment-policy estimand, outcomes after treatment discontinuation remain relevant. Document the scope of withdrawal, reasons if freely provided, and any agreed safety arrangements or remaining assessments.

Apply it

A participant stops tablets because of tolerability but is willing to attend outcome visits. The coordinator confirms the distinction, informs the investigator, schedules permitted follow-up, and documents both treatment cessation and the participant's agreement to continued assessments.

Common pitfall: Automatically canceling all visits after product discontinuation loses relevant outcomes. Conversely, consent to earlier participation does not authorize contact beyond a participant's later choices.

ICH E9(R1) — Addendum on Estimands and Sensitivity Analysis in Clinical Trials · ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

15.How can recruitment protect voluntariness and address conflicting interests?

Recruitment should present a balanced account of research, avoid promises of benefit, and preserve freedom to decline without loss of appropriate care. Consider dependency, financial circumstances, and relationships that could create pressure. Financial or professional interests that may influence judgment require disclosure and management. Compensation should be transparently described and appropriately reviewed; its acceptability depends on context, including burden and whether payment arrangements could undermine voluntary decisions.

Apply it

A clinician recruiting their own patients proposes an advertisement promising superior treatment and a large completion-only payment. The coordinator raises the misleading benefit claim and pressure concerns for investigator and ethics review before the material is used.

Common pitfall: High enrollment demand does not justify overstating benefit. Disclosure of a financial interest alone may be insufficient when the conflict also needs active management.

WMA Declaration of Helsinki — October 2024 Revision · ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

16.How should abnormal results and adverse events be followed through resolution?

A safety workflow must connect receipt of a result to qualified review, clinical assessment, necessary action, reporting, and follow-up. An abnormal value is not automatically an adverse event, but it must be assessed in context rather than ignored because the participant feels well. Track unresolved events and required reassessments until an appropriate endpoint is reached, such as resolution, stabilization, or another protocol-defined and medically justified disposition.

Apply it

A central laboratory posts a critical result after clinic hours. The coordinator activates the established alert route, confirms investigator review and participant contact, documents actions, and tracks repeat testing and any required adverse-event follow-up to completion.

Common pitfall: Entering a result into the database does not establish that anyone assessed its clinical significance. Filing an initial event report likewise does not complete follow-up.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

Product Development and Regulation13%

17.How do development objectives change across clinical studies?

Clinical development moves from establishing an initial human safety and pharmacologic understanding toward exploring efficacy, confirming benefit-risk, and learning about use after authorization. Objectives may overlap, and phase labels alone do not establish a study's procedures or evidentiary strength. Examine the actual question, population, exposure, comparator, and endpoints. Medicinal-product phase terminology should not be imposed automatically on device development, which has its own product-specific evaluation considerations.

Apply it

A study labeled exploratory tests several dose levels and collects preliminary efficacy outcomes. The coordinator reads its objectives and monitoring requirements rather than assuming that an efficacy endpoint makes the study a definitive confirmation of clinical benefit.

Common pitfall: Treating phases as rigid boxes obscures overlapping objectives. A later phase also does not eliminate the need for ongoing safety evaluation and participant protection.

ICH E8(R1) — General Considerations for Clinical Studies

18.What makes ethics review independent and fit for purpose?

An ethics committee protects participants' rights, safety, and well-being by reviewing the protocol, consent materials, recruitment arrangements, and supporting information. ICH E6(R3), section 1.3.1, recommends at least five members, including at least one member whose primary area of interest is not in medical sciences and at least one member independent of the institution or trial site. A scientist working outside medical sciences can satisfy the first recommendation; 'nonscientific' is not an equivalent qualification. Distinguish these ICH membership recommendations from jurisdiction-specific legal requirements. Only members independent of the investigator and sponsor should vote or provide an opinion, and only members participating in the review and discussion should do so. Decisions require the quorum specified in documented procedures. The investigator may provide information but should not participate in deliberations or voting.

Apply it

When checking committee composition, a coordinator identifies a physicist whose primary interest is outside medical sciences. That member can satisfy the relevant ICH recommendation despite having scientific expertise. The coordinator separately checks institutional independence, voting eligibility, quorum, and applicable legal requirements. For a revised recruitment brochure, sponsor agreement does not replace the required ethics review before use.

Common pitfall: Treating 'not in medical sciences' as meaning 'nonscientific' incorrectly narrows the ICH recommendation. Also distinguish independence from the institution or trial site, which concerns recommended membership composition, from independence of the investigator and sponsor, which determines eligibility to vote or provide an opinion. Expertise alone does not establish independence.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · WMA Declaration of Helsinki — October 2024 Revision

19.Why are prospective registration and results dissemination separate obligations?

Prospective public registration creates a visible record of a study before participant recruitment, helping counter selective visibility of research. Results dissemination addresses what the study ultimately found, including negative or inconclusive findings. Registration alone does not fulfill the responsibility to make results publicly available. Follow the relevant registration and reporting arrangements, maintain accuracy when study details change, and distinguish public study information from confidential participant-level records.

Apply it

A completed trial has a public registration entry but no results communication because the primary endpoint was not met. The coordinator alerts the responsible study team that an unfavorable finding does not remove dissemination responsibilities.

Common pitfall: Publishing only favorable outcomes distorts the evidence base. Posting a registration record at study completion also cannot provide the transparency achieved by prospective registration.

WMA Declaration of Helsinki — October 2024 Revision

20.When can an approved protocol amendment be implemented?

Implementation requires the approvals and authorizations applicable to the change, together with operational readiness. A sponsor-issued amendment is not automatically effective at every site. Confirm ethics and regulatory requirements, distinguish changes requiring prior approval from permitted exceptions, and align consent documents, systems, supplies, and staff training. Changes necessary to eliminate an immediate hazard follow the protective exception, with prompt documentation and notification rather than routine prospective implementation.

Apply it

An amendment adds a biopsy and revised consent language. Although the sponsor distributes it Monday, the coordinator retains the existing approved procedures until required approvals are documented and staff, scheduling, and consent materials are ready.

Common pitfall: Using the newest version solely because it arrived first can expose participants to unapproved procedures. Approval without operational preparation can also produce inconsistent site conduct.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

21.How do monitoring, auditing, and regulatory inspection differ?

Monitoring provides sponsor oversight of trial progress, participant protection, and data quality during conduct. An audit is a systematic, independent examination of trial-related activities and records. An inspection is an official review by a regulatory authority. Each can identify deficiencies, but their authority and purpose differ. Prepare by maintaining accessible, trustworthy records and knowledgeable staff rather than reconstructing an appearance of compliance immediately before a scheduled review.

Apply it

A regulatory authority requests records and staff interviews. The coordinator follows the inspection response process, arranges controlled access to original records, tracks requests, and records responses without treating the visit as an ordinary monitoring appointment.

Common pitfall: Backdating a missing training record to make a file appear complete creates an integrity problem. Explain the actual gap and corrective action using truthful documentation.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

22.How do site safety reports support expedited sponsor reporting?

Investigators should report serious adverse events immediately to the sponsor after becoming aware of them, except events that the protocol identifies as not requiring immediate reporting, and promptly provide follow-up information. This site obligation differs from the sponsor's expedited reporting to authorities. Under ICH E2A, an individual reaction qualifies for that category when it is serious, unexpected, and has a reasonable suspected causal relationship to the medicinal product. An adverse event does not become a suspected reaction merely because it occurred after dosing. Unexpectedness concerns whether the reaction's nature or severity is consistent with the applicable product information. Fatal or life-threatening unexpected suspected reactions require reporting as soon as possible, within seven calendar days after the sponsor first knows that the case qualifies, followed by a fuller report within eight additional calendar days. Other serious unexpected suspected reactions require reporting as soon as possible, within fifteen calendar days. Minimum case information comprises an identifiable patient, an identifiable reporting source, a suspect medicinal product, and a serious unexpected event or outcome with a reasonable suspected causal relationship. Applicable regulatory requirements govern the actual submissions.

Apply it

An investigator reports a participant's hospitalization immediately without waiting for discharge records. If the investigator suspects the investigational product caused an unexpected, life-threatening reaction and the minimum case information is available, the sponsor initiates the seven-calendar-day reporting pathway and follows with fuller information within eight additional days. Compare a hospitalization for an injury from a documented traffic collision, assessed as unrelated to the product by both investigator and sponsor: it still requires the applicable site SAE report, but seriousness alone does not place it in E2A's individual serious unexpected suspected reaction category.

Common pitfall: Do not wait for a complete narrative before submitting an initial required site report. Conversely, do not apply the sponsor's seven- or fifteen-calendar-day authority deadlines as the site's permitted waiting period. Seriousness, unexpectedness, and suspected causality must be assessed separately. If either the investigator or sponsor suspects a causal relationship, the other's disagreement does not by itself remove an otherwise qualifying serious unexpected reaction from expedited reporting.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · ICH E2A — Clinical Safety Data Management: Definitions and Standards for Expedited Reporting

23.How can an independent monitoring committee affect study continuation?

An independent data monitoring committee evaluates accumulating information under a defined charter and may recommend continuing, modifying, or stopping a trial. Access to unblinded comparative data must be controlled so interim knowledge does not bias routine conduct. Planned interim analyses need prespecified statistical safeguards because repeated evaluation can alter error rates. A recommendation must enter the appropriate sponsor, investigator, and approval processes rather than becoming an informal site-directed protocol change.

Apply it

A monitoring committee recommends pausing enrollment after a safety review. The coordinator implements the authorized site instructions, confirms arrangements for current participants, and avoids requesting confidential treatment-group results that the blinded site team does not need.

Common pitfall: Sharing unblinded interim trends with recruiters can change enrollment or care. An informal look at favorable results does not provide a sound basis for declaring success.

ICH E9 — Statistical Principles for Clinical Trials · ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

24.How should suspected fabrication or falsification be escalated?

Fabrication invents data or observations; falsification manipulates records or processes so the research is represented inaccurately. A discrepancy alone may reflect error, so preserve evidence and distinguish observation from accusation. Escalate concerns through established investigator, institutional, and sponsor channels appropriate to the circumstances, including independent channels when necessary. Protect participants, prevent further compromised activity, and document objective facts without silently changing or destroying the records under concern.

Apply it

Repeated entries describe examinations on dates when clinic access records show no visit. The coordinator preserves the conflicting records, documents the discrepancy objectively, and uses an appropriate independent reporting route when the person implicated controls routine review.

Common pitfall: Quietly replacing suspicious values destroys the audit trail and may conceal misconduct. Confrontation without preserving evidence can also compromise a fair and effective investigation.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · WMA Declaration of Helsinki — October 2024 Revision

Clinical Trial Operations (GCPs)23%

25.How should trial duties be delegated to qualified staff?

Delegation matches a defined duty with a person whose education, training, experience, and permitted professional scope support performing it. Document the assignment and ensure study-specific preparation before work begins. A name on a delegation log is evidence of assignment, not proof of competence. The investigator retains appropriate responsibility and oversight, and medical decisions must remain with suitably qualified professionals rather than being transferred through administrative convenience.

Apply it

A new coordinator has database experience but no training in the study's safety interview. The investigator assigns data entry immediately, while delaying independent safety interviewing until appropriate training and competence are established and documented for that task.

Common pitfall: A broadly worded delegation entry cannot authorize work outside professional scope. Retrospective signatures also do not demonstrate that authorization and preparation existed when work occurred.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

26.What demonstrates active investigator oversight?

Oversight means maintaining informed control of delegated activities in proportion to their importance and risk. Evidence can include review of eligibility and safety decisions, follow-up of significant findings, supervision of staff, and confirmation that trial data are reliable. Signing documents without reviewing the underlying issues is insufficient. The investigator should know which activities are failing, who is correcting them, and whether participant protection or data reliability has been affected.

Apply it

A site has repeated delayed laboratory reviews despite complete delegation records. The investigator examines the workflow, assigns backup coverage, verifies outstanding results were assessed, and reviews performance data until the revised process is working reliably at the site.

Common pitfall: Frequent signatures do not establish meaningful oversight if critical results remain unreviewed. Delegating a task does not transfer away the investigator's responsibility to supervise it.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

27.How do sponsor, investigator, and service-provider responsibilities interact?

The sponsor organizes and oversees the trial, while the investigator is responsible for conduct at the site and appropriate participant care. Service providers may perform specified activities, but agreements must make responsibilities clear and oversight must remain effective. Transferring activities does not erase the originating party's retained responsibilities. A coordinator should identify the accountable owner of a problem and the communication route rather than assuming an outside vendor has absorbed every obligation.

Apply it

A contracted laboratory repeatedly delays urgent alerts. The coordinator informs the investigator and sponsor, confirms immediate safety coverage, and requests correction through the assigned vendor-management route instead of assuming the laboratory contract resolves the site's responsibilities.

Common pitfall: Saying the vendor owns the task can leave participant risks unmanaged. Conversely, a site should not silently assume sponsor functions without defined authority and preparation.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

28.How should feasibility distinguish potential patients from enrollable participants?

Feasibility assesses whether the site can deliver the protocol with its actual population, resources, competing studies, and time. A large diagnosis count may shrink substantially after eligibility, consent, referral access, and visit burden are considered. Use defensible assumptions and historical information where relevant. Evaluate whether safety coverage and follow-up are sustainable, not merely whether enrollment can begin, and communicate constraints before accepting a target that would encourage shortcuts.

Apply it

A clinic has 400 patients with the target diagnosis, but only 60 meet major criteria and many cannot attend weekly visits. The coordinator presents a realistic recruitment estimate and transport needs before the site commits to enrollment.

Common pitfall: Using the full clinic census as the recruitment pool exaggerates capacity. Counting the same eligible patients across competing studies also produces unrealistic commitments and timelines.

ICH E8(R1) — General Considerations for Clinical Studies · ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

29.Which capabilities should a site-selection assessment verify?

Site selection verifies whether the investigator, staff, facilities, equipment, and participant access fit the actual protocol. Demonstrate capability for critical procedures, emergency arrangements, product storage, specimen processing, and secure records. An impressive enrollment history does not establish readiness for a new technical requirement. Identify gaps, their owners, and whether they can be closed before activation; unresolved limitations affecting safety or essential outcomes may make the site unsuitable.

Apply it

A proposed site can recruit readily but lacks validated overnight freezer monitoring for a critical specimen. The coordinator identifies the gap during selection and confirms a workable storage and alarm arrangement before the site is considered ready.

Common pitfall: Assuming equipment will become available later can leave the site unable to preserve critical samples. General accreditation alone does not establish protocol-specific capability or readiness.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

30.What must be ready before a site begins enrollment?

Initiation translates the approved study into a functioning site process. Confirm required approvals, current documents, qualified and trained staff, delegated duties, working systems, suitable supplies, and safety communication routes. Resolve critical readiness gaps before activation. A completed initiation meeting is not itself permission to enroll; the site must also satisfy the sponsor's activation conditions and applicable requirements, with evidence that essential participant-facing activities can be performed correctly.

Apply it

The initiation meeting is complete, but the site has no functioning emergency unblinding access. The coordinator treats this as an unresolved readiness issue and obtains correction and the required activation confirmation before scheduling research enrollment activities.

Common pitfall: A calendar invitation or training attendance sheet does not establish operational readiness. Starting early to meet recruitment targets can expose participants to preventable process failures.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

31.How should training establish competence rather than attendance?

Training should match the assigned task, the person's existing knowledge, and the risk of error. Attendance documents exposure to information; competence requires evidence that the person can apply the relevant requirements. Demonstration, supervised practice, or focused discussion may be appropriate. Update preparation when duties or procedures change. Excessive generic retraining can obscure the actual gap, whereas targeted instruction and verification address the mechanism causing errors in practice.

Apply it

After a specimen-processing amendment, staff watch a demonstration and then perform the new timed separation process under observation. The coordinator records the procedure version, training date, participants, and confirmation that each assigned person can perform it.

Common pitfall: A signed slide deck cannot prove a complex procedure was understood. Repeating general GCP training is unlikely to correct an unclear specimen-processing instruction by itself.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

32.How do critical-to-quality factors guide proportional oversight?

Critical-to-quality factors are attributes whose integrity is fundamental to participant protection or reliable study conclusions. Identify them from the study question and design, then focus prevention and review on risks that could materially affect them. Proportionality means matching controls to risk and importance, not reducing standards arbitrarily. A minor formatting inconsistency generally warrants a different response from missed primary-endpoint assessments or failures to review urgent safety results.

Apply it

A site has limited review capacity and two recurring problems: inconsistent binder tabs and missed primary-outcome visits. The coordinator prioritizes analysis and prevention of missing outcomes while correcting the filing issue through a simpler administrative process.

Common pitfall: Treating every discrepancy as equally important can divert attention from meaningful risk. Risk-based oversight still requires justified controls and follow-through for critical trial processes.

ICH E8(R1) — General Considerations for Clinical Studies · Interpretation and Application of ICH E6(R3) — Module 1.3 Transcript

33.How should monitoring methods reflect trial risks?

Monitoring may combine on-site, remote, and centralized approaches according to the study's risks, processes, and data. The aim is to detect and address threats to participant protection and reliable results, rather than to maximize visits or compare every field mechanically. Central patterns can reveal problems that isolated record checks miss. A site should support authorized access, respond to findings, and recognize when emerging risks justify modifying monitoring activities.

Apply it

Central review detects unusually few adverse events at one site despite similar participant characteristics. The coordinator supports a focused review of safety interviewing, source documentation, and reporting practices instead of treating low event counts as proof of safety.

Common pitfall: More visits do not automatically produce better oversight. Conversely, remote monitoring does not justify leaving a critical problem unresolved when direct assessment is needed.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

34.How should monitoring findings be tracked to meaningful closure?

A finding should have an understandable description, an accountable owner, an appropriate due date, and evidence supporting closure. Correct the individual issue and assess whether it signals a broader process problem. Communication must reach people able to act, especially when safety or critical data are affected. Closing an item means the required action is complete and supported, not merely that someone replied to the monitor's message.

Apply it

A monitor identifies three unsigned eligibility assessments. The coordinator arranges investigator review using available contemporaneous evidence, records truthful late endorsements, checks for additional affected participants, and supplies completion evidence without backdating the original assessments or signatures.

Common pitfall: Marking an item closed after promising action conceals unfinished work. Backdating a correction also creates an additional integrity problem instead of resolving the original finding.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

35.How do correction and root-cause analysis differ in CAPA?

A correction addresses an identified problem, such as completing an overdue review. Root-cause analysis investigates why the failure occurred so corrective action can prevent recurrence and preventive measures can address related risks. Look beyond labels such as human error to workflow, access, workload, instructions, and handoffs. The depth of analysis should reflect the issue's significance, with immediate containment when ongoing participant risk or data compromise is possible.

Apply it

Several critical results were not reviewed during leave coverage. Completing those reviews corrects the backlog; investigating the absent backup assignment identifies the cause. The coordinator helps introduce a named coverage roster and an escalation trigger for unacknowledged results.

Common pitfall: Writing retrain staff as the entire CAPA skips the causal question. Training will not fix a workflow in which no backup reviewer is assigned.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

36.How can a CAPA plan demonstrate effectiveness?

A useful CAPA plan specifies actions, responsible people, completion dates, and an effectiveness measure linked to the failure mechanism. Implementation shows that a change occurred; effectiveness shows that it works. Choose a meaningful period or sample of activity and define the success criterion before evaluation. If failures persist, reassess the cause and controls rather than repeatedly declaring the same completed action successful without evidence of improved performance.

Apply it

After missed safety alerts, the site installs a backup notification route. Its effectiveness check reviews the next 20 alerts for acknowledgment within the study-defined interval, including weekend events, and triggers reassessment if any remain unacknowledged.

Common pitfall: Counting staff who attended retraining measures implementation, not necessarily improvement. A success criterion unrelated to the original failure can make an ineffective CAPA appear complete.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

37.When does noncompliance require escalation beyond routine correction?

Evaluate noncompliance by its impact or potential impact on participant rights, safety, well-being, and the reliability of results, including whether it is repeated or systemic. Significant problems require prompt escalation, investigation, and appropriate corrective and preventive action. Necessary notifications depend on responsibilities and applicable requirements. Do not let a seemingly small individual departure obscure a pattern, or wait for proven harm when the process creates a substantial ongoing risk.

Apply it

A site repeatedly uses an obsolete consent form that omits a newly identified serious risk. The coordinator immediately alerts the investigator and sponsor, identifies affected participants, and supports protection, assessment, required reporting, and corrective action at the site.

Common pitfall: Treating each obsolete form as an isolated clerical error misses the systemic consent failure. Actual injury is not required before a significant protection issue merits escalation.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

38.What makes study close-out complete?

Close-out verifies that participant responsibilities, safety follow-up arrangements, data issues, product disposition, and essential records are appropriately resolved or assigned. Confirm required reports, record custody, retention arrangements, and continuing access. The final visit does not end every obligation: unresolved safety events, later data questions, or inspections may still require action. Distinguish operational closure from permission to destroy records or discontinue agreed participant care and communication.

Apply it

At close-out, product reconciliation is complete but two safety events remain under follow-up. The coordinator records who will obtain updates, how the sponsor will receive them, and where records will remain accessible after routine site activity ends.

Common pitfall: A signed close-out report does not authorize record destruction. Assuming the monitor's departure ends all participant follow-up can leave safety obligations without an owner.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

Study and Site Management22%

39.How should important trial communications be documented?

Document communications that explain significant decisions, instructions, approvals, or unresolved issues affecting trial conduct. The record should identify participants, date, subject, decision, responsible owner, and necessary follow-up. Use the appropriate controlled repository so the information remains available to the people who need it. An undocumented verbal instruction is especially problematic when it changes a process, while storing every routine message without organization can make important decisions difficult to find.

Apply it

During a call, the sponsor clarifies which laboratory result determines a visit window. The coordinator records the question and approved clarification, confirms it in writing, and distributes it to staff responsible for scheduling and source documentation.

Common pitfall: A private inbox is a fragile sole repository for essential decisions. Verbal sponsor advice also cannot substitute for a required protocol amendment or approval.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

40.How should contracts and budgets reflect the work a protocol creates?

A workable agreement connects defined responsibilities and financial arrangements to the actual protocol workload. Consider scheduled and conditional procedures, start-up effort, participant reimbursements, data work, safety follow-up, pharmacy and laboratory services, and record retention. Identify who pays, what documentation supports payment, and how changes are handled. Budget assumptions must not encourage omitting required care or paying only for favorable outcomes; financial arrangements support compliant conduct rather than overriding it.

Apply it

An amendment adds unscheduled safety visits and extra specimen shipments. Before accepting the revised workload, the coordinator identifies affected departments and helps document the additional activities, payment triggers, and contractual changes needed to resource them appropriately.

Common pitfall: A per-participant payment alone may omit substantial conditional work. A funding dispute does not justify withholding clinically necessary attention or silently dropping required trial activities.

2024 Examination Content Outline: CCRC® Certification · ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

41.How can visit scheduling preserve protocol windows and meaningful assessments?

Translate protocol timing into a participant calendar using the correct anchor, permitted windows, preparation requirements, and dependencies among procedures. A visit inside its date window can still be noncompliant if sampling order or time relative to dosing is wrong. Plan around holidays, staff availability, and participant burden, with contingencies for disruptions. Track enrollment and data deadlines without moving assessments merely to make a milestone appear complete.

Apply it

A visit is allowed on days 26 through 30, but the pharmacokinetic sample must precede dosing. The coordinator schedules day 28, confirms the participant will not take the morning dose beforehand, and alerts the collection team.

Common pitfall: Using calendar month dates instead of protocol study days can shift windows. A convenient appointment does not justify changing a required sequence or timing anchor.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

42.How should equipment readiness be verified for trial measurements?

Equipment must be suitable for its intended measurement and maintained or calibrated as appropriate. Confirm status before use, retain evidence, and have a contingency when a critical device fails. If equipment is later found outside acceptable performance, assess which participant measurements or stored materials may be affected. A maintenance sticker is useful only when it corresponds to the correct device and supported service record, not as a substitute for evaluation.

Apply it

A centrifuge's speed verification is overdue before a critical specimen collection. The coordinator arranges an approved, verified alternative and asks the responsible team to assess whether earlier processing could have been affected by the equipment gap.

Common pitfall: Assuming a device is reliable because it turns on confuses function with measurement suitability. Recalibration does not automatically validate all results produced before the problem.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

43.How can supply management prevent avoidable protocol departures?

Maintain supplies according to expected enrollment, visit schedules, expiration dates, shipping lead times, and storage requirements. Distinguish superficially similar kits by their intended tests, preservatives, and processing instructions. Reorder before the stock reaches a level that threatens scheduled activities, and remove expired or unsuitable supplies from usable inventory. Substitution requires confirmation of suitability and authorization when applicable; availability alone does not establish equivalence for a study-specific collection or procedure.

Apply it

A site has enough tubes for next week's visits, but several expire beforehand and replacement kits take ten days. The coordinator identifies the usable stock deficit early and arranges an authorized supply solution before participants attend.

Common pitfall: Counting expired kits as available stock hides a shortage. A similar-looking tube may contain a different additive and cannot be assumed interchangeable for the assay.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

44.What should be checked when investigational product arrives?

On receipt, reconcile the shipment against its documentation and inspect identity, quantity, kit or batch identifiers, expiry, packaging integrity, and required transport conditions. Record receipt and place the product in appropriate controlled storage. Segregate discrepancies or potentially compromised stock until disposition is authorized. A delivery signature establishes arrival, but does not demonstrate that the shipment is complete, suitable for dispensing, or maintained within its required conditions.

Apply it

A shipment contains the expected number of kits, but the transport monitor shows an excursion. The coordinator documents the finding, separates the affected stock, and obtains the responsible product-quality assessment before any kit is made available.

Common pitfall: Intact packaging does not rule out temperature damage. Adding a questioned shipment directly to usable inventory can allow dispensing before its suitability has been established.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

45.How should a product storage excursion be managed?

A storage excursion requires prompt protection of affected stock, preservation of temperature and timing evidence, and assessment through the designated product-quality route. Identify the product, duration, conditions, and whether any affected units were dispensed. Keep stock segregated from usable inventory until its disposition is authorized. Restore the storage system and investigate the cause, but do not equate a return to normal temperature with proof that prior exposure was harmless.

Apply it

A refrigerator alarm reveals an overnight temperature rise. The coordinator secures affected kits, saves the logger record, checks dispensing since the event began, and seeks documented disposition while arranging suitable storage and assessment of the failure.

Common pitfall: Discarding stock immediately can destroy evidence and create unnecessary loss. Releasing it solely because the refrigerator now reads correctly ignores the product's exposure history.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

46.How does product accountability reconstruct each unit's disposition?

Accountability records connect receipt, storage inventory, participant dispensing, returns, and final disposition using relevant identifiers and dates. Reconciliation compares physical stock with the documented transactions and investigates differences. Separate returned or unusable product from stock available for dispensing. The objective is a traceable history, not merely a balanced total: matching arithmetic can still conceal dispensing to the wrong participant or using an expired kit if identifiers are ignored.

Apply it

A site received 120 units, dispensed 80, returned 10 unused dispensed units, and holds 40 never dispensed. The coordinator verifies both usable inventory and segregated returns, matching transactions to participant and kit records before disposition.

Common pitfall: Adding returned units directly to usable inventory can permit unauthorized redispensing. A balanced count does not resolve mismatched kit identifiers or unexplained changes in custody.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

47.How can dispensing preserve assignment, labeling, and blinding?

Dispensing should verify participant identity, the authorized assignment, correct kit, current suitability, and required instructions without revealing treatment unnecessarily. Use the designated allocation system and preserve required labeling and packaging. Similar appearance does not make kits interchangeable, and a system outage does not authorize staff to infer assignments. Document the transaction so another reviewer can connect the participant, date, quantity, and product identifier to the authorized dispensing decision.

Apply it

The allocation system assigns kit 714, but a nearby kit has similar packaging and an earlier expiry. The coordinator dispenses the assigned suitable kit after verification rather than substituting stock to simplify inventory rotation.

Common pitfall: Choosing any visually identical kit can break treatment assignment. Removing packaging to make transport easier can also remove required identifiers or compromise blinding and instructions.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

48.How should participant adherence be assessed without assuming ingestion?

Adherence assessment combines available evidence, such as participant discussion, diaries, dispensing history, and returned product counts. A count estimates use but does not prove ingestion or correct timing. Explore discrepancies neutrally to identify misunderstanding, tolerability problems, access barriers, or deliberate nonuse. Document the findings and involve the investigator when safety or interpretation is affected. Reinforce approved instructions without inventing replacement dosing advice for missed or uncertain doses.

Apply it

A participant received 30 tablets, reports taking one daily for 28 days, and returns eight. The coordinator notes that 22 tablets are unaccounted for as used, explores the discrepancy, and seeks investigator guidance rather than assuming 28 doses.

Common pitfall: Accusing the participant of dishonesty can suppress useful information. Calculating an apparently precise adherence percentage does not establish whether tablets were actually swallowed as directed.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

49.Which specimen collection details protect the validity of an assay?

Specimen validity depends on the right participant, collection time, container, preparation, and processing conditions. Record actual collection and processing times when they affect interpretation, and follow the study's sequence relative to dosing or other procedures. A correctly labeled tube can still be unsuitable if the wrong additive, centrifugation conditions, or delay alters the analyte. Document departures truthfully and obtain an assessment rather than modifying times to create apparent compliance.

Apply it

A biomarker sample must be separated within 30 minutes, but separation occurs at 50 minutes. The coordinator records the actual times, informs the responsible team, and checks whether the sample remains interpretable or recollection is permitted.

Common pitfall: Changing the recorded time conceals a preanalytical problem and creates false data. Recollecting without considering the required time relative to dosing may not restore validity.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

50.How should specimen storage and shipment maintain traceability?

Maintain a traceable link from collection to storage location, shipment, and receipt while limiting unnecessary identifiers. Confirm required temperature, packaging, shipment timing, and receiving-laboratory availability. Record transfers and investigate missing, delayed, damaged, or temperature-compromised material. A courier pickup is only one step in the chain; receipt and suitability may still need confirmation. Follow applicable transport requirements without assuming that all specimens share the same packaging or temperature conditions.

Apply it

A frozen shipment is scheduled before a local holiday at the receiving laboratory. The coordinator checks acceptance arrangements and validated holding options, then reschedules within permitted stability limits instead of sending samples into an unattended delivery queue.

Common pitfall: A tracking number does not prove the laboratory received usable samples. More cooling is not automatically better when an assay requires a different validated condition.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

51.How should a site oversee vendors that support critical activities?

Vendor management establishes the service, responsibilities, quality expectations, communication routes, and escalation arrangements before relying on an external provider. Confirm capability for the study-specific task and monitor performance proportionately to its importance. Outsourcing a courier, laboratory, translation, or equipment service does not remove the need to ensure participant protection and trustworthy results. Repeated failures require assessment of impact, corrective action, and potentially an alternative arrangement rather than repeated informal reminders.

Apply it

A contracted courier misses two time-sensitive pickups. The coordinator documents affected specimens, assesses stability with the laboratory, escalates through the agreed service owner, and helps establish a reliable backup while the provider addresses the recurring failure.

Common pitfall: Assuming a contract guarantees performance leaves failures unmanaged. Changing vendors without confirming training, specifications, and handoffs can replace one uncontrolled process with another at the site.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

Data Management and Informatics15%

52.How do source records and case report forms serve different purposes?

Source records capture original observations and relevant context; case report forms collect the protocol-required information reported to the sponsor. The same system can sometimes serve both roles when appropriately defined and controlled. Identify the source for each important data type before collection and preserve traceability. Source data verification compares reported values with source, while source data review also evaluates the quality and context of the underlying trial documentation and conduct.

Apply it

A symptom score is entered directly by the participant into a designated electronic system. The coordinator treats that original entry as source according to the data plan rather than creating a retrospective paper copy as the supposed original.

Common pitfall: Assuming every electronic case report form is source can obscure transcription steps. Conversely, requiring paper duplication of valid electronic source may create conflicting versions unnecessarily.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

53.How does ALCOA+ distinguish trustworthy data from merely complete forms?

Trustworthy records are attributable, legible, contemporaneous, original, and accurate, with completeness, consistency, endurance, and availability across their useful life. These properties connect a value to who observed it, when it was obtained, and how it can be understood and reviewed. A completed field may still fail these standards if it was guessed, backdated, copied without context, or stored in a format that cannot remain accessible during retention.

Apply it

A coordinator notices that an examination field was completed days later from memory. The coordinator documents the timing and available supporting evidence honestly, distinguishes reconstruction from contemporaneous observation, and escalates uncertainty instead of presenting the entry as original.

Common pitfall: Neatness and absence of blanks do not establish accuracy. Filling missing observations from assumptions can make a record look complete while undermining its reliability substantially.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

54.How should corrections preserve the original record and its meaning?

A correction must be attributable, supported, and traceable without obscuring the original entry. Electronic audit trails should preserve relevant changes and associated metadata, including who changed what and when. Record the reason when needed to understand the correction. A later amendment may accurately clarify a record, but it cannot transform an unobserved measurement into a contemporaneous fact. Preserve context and obtain appropriate investigator review or endorsement of reported data.

Apply it

A transcribed visit date differs from the contemporaneous clinic record. The authorized coordinator corrects it using that source, records the reason, and retains the electronic history rather than deleting the original entry or modifying its timestamp.

Common pitfall: A technically editable field is not permission to overwrite history. Backdating an entry to match the visit date misrepresents when documentation actually occurred in the record.

Interpretation and Application of ICH E6(R3) — Module 3.4a: Data Lifecycle Management

55.How should a data query be resolved when the requested value is uncertain?

A query requests clarification of missing, inconsistent, implausible, or otherwise questionable data. Resolve it by reviewing appropriate source and context, then correcting or explaining the reported information through an attributable process. The wording of a query does not establish the truth of its suggested answer. If a fact cannot be verified, preserve that uncertainty and follow the defined missing-data approach rather than choosing a plausible value simply to close the query.

Apply it

A query asks whether an undocumented examination was normal. The coordinator checks available records and asks the appropriate investigator for clarification. If no observation can be supported, the response identifies the information as unavailable instead of normal.

Common pitfall: Treating query closure as the goal encourages unsupported data cleaning. A clinically plausible value can still be false when the assessment was never documented or performed.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

56.How should electronic access follow individual roles and responsibilities?

Access controls should identify individual users and limit functions and information to their authorized responsibilities. Provide access after appropriate authorization and training, review it when duties change, and remove it when no longer needed. Shared credentials weaken attribution and make it difficult to reconstruct who entered or changed data. Secure access must also remain workable during legitimate coverage so urgent safety information is not trapped behind an unavailable individual's account.

Apply it

A departing coordinator's replacement needs database access. The site requests an individual account with appropriate permissions and removes the former user's access, rather than sharing the old login to avoid a delay in routine data work.

Common pitfall: A shared team account makes entries difficult to attribute. Granting administrator privileges to solve a narrow access problem can expose unnecessary functions and confidential information.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

57.How can data transfers compromise blinding even without treatment labels?

Treatment identity may be revealed by direct assignment fields or indirectly through filenames, kit patterns, pharmacologic measurements, and linked metadata. Plan transfer content and access according to who may receive blinded or unblinded information. Verify the transfer, mapping, and intended recipients before release, using controls proportionate to the risk. Removing a treatment column is insufficient when other variables allow blinded personnel to infer assignments and potentially bias ongoing assessments.

Apply it

A laboratory export for blinded assessors omits treatment names but includes a drug concentration that identifies active treatment. The coordinator flags the disclosure risk and routes the export for an appropriately restricted or revised transfer before release.

Common pitfall: Checking only column headings misses indirect disclosure. Once treatment identity is exposed, deleting the file may limit further access but cannot restore the recipient's prior blinding.

Interpretation and Application of ICH E6(R3) — Module 3.2: Risk-Proportionate Approach to Data Governance

58.Why must safety and clinical databases be reconciled?

Clinical and safety systems serve related but different purposes and may receive information at different times. Reconciliation checks that shared facts, such as event identity, seriousness, onset, outcome, and relevant treatment exposure, are consistent or have an explained difference. Prompt safety reporting must not wait for routine database completion. A discrepancy should be investigated using source and responsible assessments rather than making one system match the other without determining which information is correct.

Apply it

The safety system lists an event as ongoing, while the case report form shows recovery. The coordinator reviews follow-up evidence, confirms the investigator's assessment, and updates the appropriate systems with a traceable explanation for the corrected outcome.

Common pitfall: Automatic copying can spread an error into both systems. Agreement between databases does not prove accuracy unless the shared information is supported by reliable underlying records.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025

59.What makes an essential-record repository usable throughout the trial?

Essential records allow evaluation of trial conduct, participant protection, and the reliability of results. They may reside across paper and electronic systems if their locations, control, access, and relationships are understood. Maintain current versions where used and preserve relevant superseded versions as evidence of historical conduct. A repository is useful when authorized reviewers can locate understandable records with their context, rather than when every document has merely been uploaded somewhere.

Apply it

Consent approvals are stored in an ethics portal, while training records are local. The coordinator maintains a clear record-location plan and secures continuing access or appropriate copies before the portal account closes at the end of the study.

Common pitfall: Uploading a file without its version or approval context can make it uninterpretable. Depending on temporary portal access may leave essential records unavailable after close-out.

Interpretation and Application of ICH E6(R3) — Module 5.2 Transcript

60.When can a certified copy support retention or replacement of records?

A certified copy is verified, through a dated signature or validated process, as containing the same information as the original, including relevant context, content, and structure. A simple scan is not automatically certified, and a static image may omit meaningful electronic metadata. Under E6(R3), section 2.12.12, investigator records must be retained for the applicable regulatory period or until the sponsor notifies the investigator that they are no longer needed, whichever is longer. This applies to retained originals or acceptable certified replacements, which must remain accessible and intact. Certification alone does not end retention. Before replacing or destroying originals, confirm certification adequacy, applicable requirements, responsible authorization, and any continuing preservation need.

Apply it

A site plans to discard paper worksheets after scanning. The coordinator confirms a controlled certification process, legibility and completeness checks, retention arrangements, and required authorization before any original is considered eligible for destruction under applicable requirements. Acceptable certified replacements remain subject to the longer of the regulatory retention period and the period ending with sponsor notification that the records are no longer needed.

Common pitfall: A readable PDF alone does not establish a certified copy. Study completion, certification, or sponsor notification before the regulatory period expires does not independently authorize ending retention.

ICH E6(R3) Guideline for Good Clinical Practice — Final, January 6, 2025 · Interpretation and Application of ICH E6(R3) — Module 5.2 Transcript

What to focus on during revision

The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.

  • Give the greatest study time to Clinical Trial Operations and Study and Site Management, while maintaining deliberate coverage of all six official domains.
  • Separate seriousness, severity, causality, and expectedness before deciding how a safety event enters reporting and follow-up workflows.
  • Practise consent as continuing communication: understanding, voluntariness, new information, assent, and the scope of withdrawal.
  • Trace responsibility through investigator delegation, sponsor oversight, service-provider agreements, and escalation routes.
  • Use risk and critical-to-quality factors to distinguish cosmetic deficiencies from threats to participant protection or reliable conclusions.
  • Reconstruct product and specimen histories from identifiers, conditions, timestamps, transfers, and authorized disposition.
  • Resolve queries and corrections from supported observations while preserving uncertainty, attribution, original entries, and relevant metadata.
  • Keep the 2024 outline, the January 2025 E6(R3) adoption, and the July 2026 examination-reference transition distinct.

A practical preparation plan

1. Map the full outline to your experience

Review every official knowledge and task statement. Mark each as something you can explain, apply with help, or cannot yet perform. Use the 60 concepts as focused teaching points while retaining the complete outline as your coverage map.

2. Build decision chains from the primary references

For each weak area, connect the triggering observation to the governing principle, responsible decision-maker, immediate action, required documentation, and follow-up. Start with consent, serious events, delegation, product excursions, and data corrections.

3. Work cases with explicit distinctions

Explain why a serious event need not be severe, why product cessation need not end outcome collection, and why a corrected record must preserve history. Add eligibility, screening-rate, accountability, and adherence calculations using clearly defined denominators.

4. Use the questions diagnostically

Answer each drill before reading its explanation. For every error, identify the decisive cue and explain why each alternative fails. Link the gap to an official outline statement rather than treating a small question set as a readiness score.

5. Repeat recall and rehearse integrated workflows

Space flashcard practice across several sessions, then combine topics in a mock site day: a safety alert, an amendment, a storage excursion, and a query. Explain ownership, participant protection, documentation, and closure for each event.

Use your sample score as a starting point

The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.

Start the free sample

Official sources and updates

Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.